Published in TB and Outbreaks Week, September 23rd, 2003
No deal has been made, and the company's vaccine is still years away from gaining regulatory approval. Still, the company's stock closed up nearly 23% on the announcement.
Brisbane-based VaxGen issued a news release that said it was negotiating with the Health Protection Agency for England and Wales.
VaxGen is developing the vaccine, dubbed rPA102, under a $16.2 million contract from the National Institute of Allergy and Infectious Diseases, one of the U.S. National...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.